Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
516.56
+3.35 (0.65%)
Sep 25, 2026, 4:00 PM EDT - Market closed

Madrigal Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 19 analysts polled by S&P Global, Madrigal Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $682.11. The average 1-year stock price forecast is 32.05% higher than the current stock price, while the lowest is $543 (+5.12%) and the highest is $962 (+86.23%).

Price Target: $682.11 (+32.05%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$543$682.11$661$962
Change+5.12%+32.05%+27.96%+86.23%

Analyst Ratings

The average analyst rating for Madrigal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy111111111213
Buy333333
Hold222221
Sell000000
Strong Sell000000
Total161616161717

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Goldman Sachs
Goldman Sachs
Buy
Initiates
$704
BuyInitiates$704+36.29%Sep 24, 2026
Citi
Citi
Buy
Initiates
$725
BuyInitiates$725+40.35%Sep 23, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Reiterates
$612
BuyReiterates$612+18.48%Aug 12, 2026
Wolfe Research
Wolfe Research
Buy
Upgrades
$605
BuyUpgrades$605+17.12%Aug 4, 2026
Barclays
Barclays
Buy
Maintains
$964 → $962
BuyMaintains$964 → $962+86.23%Aug 3, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.53B
from 958.40M
Increased by 59.37%
Revenue Next Year
2.13B
from 1.53B
Increased by 39.35%
EPS This Year
-6.49
from -12.73
EPS Next Year
9.63
from -6.49
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
---180.13M958.40M1.53B
Revenue Growth
----432.05%59.37%
Gross Profit
---173.90M902.26M1.38B
Gross Margin
---96.54%94.14%90.52%
Operating Income
-242.48M-293.57M-380.50M-497.88M-300.10M-186.79M
Net Income
-241.85M-295.35M-373.63M-465.89M-288.28M-183.02M
EPS
-----12.73-6.49
Free Cash Flow
-----190.02M-200.50M
No. Analysts
-----18
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High1.6B
Avg1.5B
Low1.5B

Revenue Growth

Revenue Growth202620272028
High
64.8%
Avg
59.4%
Low
54.3%

EPS Forecast

EPS202620272028
High-4.91
Avg-6.49
Low-7.38

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-